Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12169328 | 0.89 | ALDH1A1 (0.63) | ALDH1A1KDM4EPKMHTTPOLB | |
| SCHEMBL12169326 | 0.77 | ALDH1A1 (0.62) | ALDH1A1KDM4EPKMHTTPOLB | |
| SCHEMBL8879797 | 0.76 | CYP2D6 (0.66) | ALDH1A1KDM4EPKMHTTPOLB | |
| SCHEMBL7461134 | 0.76 | ALDH1A1 (0.57) | ALDH1A1KDM4EPKMHTTPOLB | |
| SCHEMBL2474562 | 0.76 | ALDH1A1 (0.62) | ALDH1A1KDM4EPKMHTTPOLB | |
| SCHEMBL12228354 | 0.76 | LMNA (0.71) | ALDH1A1PKMHTTPOLBKMT2A | |
| SCHEMBL14086755 | 0.76 | ALDH1A1 (0.60) | ALDH1A1KDM4EPKMHTTPOLB | |
| SCHEMBL719913 | 0.75 | TP53 (0.45) | ALDH1A1HTTKMT2AMEN1LMNA | |
| SCHEMBL13888771 | 0.75 | ALDH1A1 (0.63) | ALDH1A1KDM4EPKMPOLBKMT2A | |
| SCHEMBL3868079 | 0.75 | ALDH1A1 (0.58) | ALDH1A1KDM4EPKMHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | GPR119, GLP1R, GIPR | ALDH1A1 1093/4885KDM4E 2180/4885PKM 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.